chart(10) 3-2008 - The Original Herpes Home Page!!

The Original HHP
SUMMARY CHART OF HERPES & HPV RESEARCH
INFORMATION AS OF 03/08/2008
COMPANY (website)
Affiliations
MISC NOTES
PRODUCT
TYPE OF PRODUCT STAGE OF
DEVELOPMENT
(P) - Prophylactic
(T) - Therapeutic
(Rx) - Treatment
DATE MOST
RECENT NEWS
(SOURCE)
dl5-29
(T) vaccine for HSV2
2/26/2008:
dl5-29 was originally
http://www.acambis.com/defa developed and researched
ult.asp?id=2052
by Dr Knipe at Harvard
Medical School
Vaccines
1)
Acambis
Cambridge,
UK and Cambridge, MA
(www.acambis.co.uk)
2)
Antigenics
New York
(www.antigenics.com)
3)
University of Washington, Westover AG702/AG707: recombinant (P)&(T) vaccine for HSV2 // AG-707: 3/28/2006:
10/16/2006:
Heights, Fred Hutchinson Cancer human heat shock protein to a monovalent vaccine
Recruiting 84 subjects for
www.clinicaltrials.gov // Study
Research Center
induce Tcell response
Phase I at Westover Heights details:
Clinic in Portland, OR and http://www.clinicaltrials.gov/ct
Seattle, Washington //
/show/NCT00231049?order=
10/16/2006: still recruiting 1
2/2008: still recruiting
Theraherp (aka ICP10?PK; (T) recombinant vaccine
genetically attenuated
aka Delta PK)
AuRx, Inc.
Maryland
(www.aurx.com)
Contact: Gary Calton (President)
4)
AusAm Biotechnologies
collaborating with NIH
ImmunoVEX hsv2
(P) and/or (Rx) vaccine for
HSV2
Preclinical // Phase I
anticipated in early 2007 in
the UK
9/5/2006:
http://www.bizjournals.com/bo
ston/stories/2006/09/04/daily2
.html?from_rss=1 //
10/16/2006: co website
seeking partner for future clinical
development
ImmunoVex HSV2/HPV:
dual vaccine for (P) and/or
(Rx) of HSV2 and HPV
Preclinical
10/16/2006: co website
2003: Tekron, Inc // Tekron &
BioVirus to form Canadian
subsidiary of BioVirus
Universal Peptide Herpetic several (P) and (T) synthetic
peptide vaccines fron viral
Vaccine
(www.virology.net/garry/fav genomes for HSVI and
HSVII
webvacc.html)
10/1/2004: Affiliation with Phanuel
Pursuits failed
Simplivir (aka CY301) anti (T) topical treatment CY301
herpes cream for HSV1 or
HSV2 to strip virus from
being able to migrate to the
nerve cell
PreClinical - continuing with 2/21/2006: email from
studies using reformulated Cytogenix 10/16/2006 co
synDNA // anticipate human website
trials in next 18-24 months
10/1/2004: Affiliation with Phanuel
Pursuits failed
CY501
(T)
Pre-Clinical
10/2006 - company website
(T) vaccine for HSV2
Pre-Clinical
3/6/2008:
http://www.genvec.com/downl
oad/press/GenVec%20HSV2
%20Grant%20Release_FINA
L%20OUT1.pdf
BioVex
BioVex
Cambridge, MA
(www.biovex.com)
7)
BioVirus Research Inc
(BioVirus Medical)
Nevada
Tekron contact: Dr. James Insell
(519)433-4400
8)
Cytogenix, Inc.
Texas
(www.cytogenix.com)
9)
Cytogenix, Inc.
Texas
(www.cytogenix.com)
10)
GenVec
12/8/2006: HHP member
Dallas phone call with Dr.
Calton: $7 million needed to
proceed and having no luck
finding funding
(T) :broadspectrum antiviral preclinical - scheduled for
therapeutic for herpes, HIV human trials late 2003
& small pox
Cambridge, MA
(www.biovex.com)
6)
pre Phase III
DES6
New York
(www.ausambiotech.com)
5)
pre-clinical with intent to
apply for IND in 2009
Fred Hutchinson Cancer Institute &
UWashington
Company Website: Info re:
AG702/AG70x:
http://www.antigenics.com/n
ews/factsheets/ag70x.pdf //
Development of AG 702 has
ceased, proceeding with
AG707
2/2005: lining up funding
source rumored on IHUB w/
Phase III to begin in 6
months (per email from Dr
Calton to Newbie)
10/16/2006: can no longer
locate website
8/3/2005: announcement of
preclinical results expected
to be announced (thanks
Anonymous!) per company
websites
11/4/2003 - Yahoo! Finance veterinary applications as
11/12/2003 - PrimeZone.com early as spring 2005
10/16/2006: co website
CEO Update:
http://www.cytogenix.com/e
n_us/Investors/p37221191.h
tml
11)
Henderson Morley
Birmingham, England
(www.henderson-morley.com)
12)
John Hopkins School of Public
Health
13)
Lund University
7/2006: HM licensed ICVT (genital
and oral herpes indications) to
Amistad Pharma (France) for
clinical development // As part of
agreement preclinical research
must be complted 18 months from
licensing date
(1) ICVT therapy
(2) Intracellular Herpes
vaccine (Skinner vaccine)
(3) Prep vaccine
(1)topical
(2) Skinner: Pre-Clinical
(P) & (T) vaccine
(3) Prep: (T) vaccine
10/16/2006: co website July Skinner may be available as
part of "Named Patient
2006 press release:
program". Register on co
http://www.hendersonwebsite:
morley.com/cgihttp://www.hendersonbin/www.hendersonmorley.com/news_and_events morley.com/main/contact_us
.html NOTE: Several people
.pl?i=73
have tried this route and
posted on HHP that they
never receive any response
(P) & (T) vaccine
Preclinical
7/30/2005:
available for licensing
http://www.jhsph.edu/TechTra
nsfer/Industry/inventions.html
Cystapep
(T)
preclinical research
12/2003 http://www.eurekalert.org/pub
_releases/2003-12/srcnwt121003.php
AD472
(T) live virus vaccine for
GHSV2
Pre-Clinical
3/19/2005 Abstract from
did not prevent infection or
virus replication in the
Journal article in Vaccine
vaginal tract, but did reduce
10/29/2005: powerpoint
both lesion development and
presentation
http://www.colorado.edu/mcd severity in a doseb/MCDB4750/presentations/H dependent manner in guinea
pigs
erpesPresentation2.ppt
11/2005: Abstract in Vaccine :
http://www.ncbi.nlm.nih.gov/e
ntrez/query.fcgi?cmd=Retriev
e&db=pubmed&dopt=Abstrac
t&list_uids=15950327&query_
hl=10&itool=pubmed_docsum
live attenuated vaccine for
ghsv1 and ghsv2
(P)
Preclinical
10/13/2006:
http://www.emaxhealth.com/4
8/7880.html
2/20/2006: company website NanoViricide is targetting the
flu virus and HIV first. It's
predicting the first FSDA
IND for this technology in
2007. Once successful for
these two indications, it
plans to apply the
technology to other
conditions including herpes
7/30/2005:
available for licensing
http://ttp.northwestern.edu/ab
stracts/viewabs.php?id=243&
cat=127
Dr. Paul Ts / Laure Aurelian
Sweden
14)
MedImmune Vaccines Inc.(California) University of Alabama School of
Medicine // Richard Spaete
(MedImmune)
15)
Montana State University
seeking partner for future clinical
development
16)
NanoViricide
www.nanoviricide.com
6/2005 Edot.com acquires
Nanoviricide // science licensed
from Theracour Pharma
17)
Northwestern University
18)
REPLICor
Montreal
(www.replicor.com/index.htm)
Preclinical
(T) HSV1 & HSV2
Preclinical
McGill Uiniversity // seeking
partners
REP 9
(T)
Preclinical
2/20/2006 - company
website: seeking partners
UF #10994
(T) vaccine
Preclinical
(T) vaccine for HSV2
Preclinical
UF marketing piece for UF
#10994:
http://apps.rgp.ufl.edu/otl/pd
f/marketing/10994.pdf#sear
ch='university%20of%20flori
da%20herpes'
NIH grant issued to Dr Koelle CMV??
at Uwash for 4/4005 11/2005
(Rx)
Preclinical
19)
University of Florida
looking for partner/funding
20)
Vical
UW, NIH
About REP9:
http://www.replicor.com/deb
ut_anglais.htm
Treatments
1)
Adventrix Pharmaceuticals
(www.adventrx.com)
NIH
Thiovir // thioanalogues
7/30/2005 - company website being studied right now for
HIV but has shown efficacy
against herpes (thanks
Anonymous!)
2)
Dr Kleymann (University of
Tubingen)
AiCuris (Bayer spin-off)
(Germany)
BAY 57-1293 (Helicase
(Rx)
inhibitor) against HSV1 and
HSV2
Preclinical
10/27/2005: email from
Bayer brochure (2003):
http://www.research.bayer.c
Bayer in response to HHP
member Samson: Bayer no om/medien/pages/2999/herp
longer pursuing BAY 57-1293 es.pdf // Dr. Kleymann holds
patent but no longer works
// implied herpes research
might be pursued when Bayer for Bayer
spinoff to Santo Holding
Deutschland AG // transaction
to be completed 1st Q 2006 //
2/22/2006: email from Dr
Kleymann: Bayer spinoff to
pickup research with BAY 571293 - were within weeks of
beginning Phase I // 4/9/2006
email from Dr. Kleymann:
AiCuris is resuming
development of BAY 57-1293.
Clinical trials won't begin
before 2007.
Phase II
11/2007: actively recruiting
subjects for studies across
US
Pre-clinical
12/2004 - Antiviral Res. 2004
Dec;64(3):161-70.
3)
Astellas Pharmaceutical
ASP 2151 (Helicase
inhibitor) against ghsv
4)
Boehringer Ingelheim Ltd
(Canada)
BILS 179 BS (Helicase
(Rx)
inhibitor) against HSV1 and
HSV2
CEL-SCI
CEL 1000 (aka derG)
5)
East West Distributors, Inc
Arizona
7)
Flamel Technologies
France
(www.flamel-technologies.fr)
8)
GlaxoSmithKline (GSK)
11/2007:
http://www.clinicaltrials.gov/
ct2/show/NCT00486200?ter
m=astellas&rank=10
(Rx) for GHSV peptide w/
Phase I/II animal studies
strong immunity stimulatory
action incl induction of
protective immune
responses
11/3/2005: presentation of
LEAPS effectiveness against
herpes in animal models //
http://www.prnewswire.com/c
gibin/stories.pl?ACCT=104&ST
ORY=/www/story/11-032005/0004207727&EDATE=
Viraplex and MTCH-24 Was originally Meditech
Pharmaceuticals, Inc which became both work against herpes
Deli Solar and East West
(12/31/2004). East West got the
pharmaceutical research.
(Rx) Viraplex for oral and
Viraplex - mid Phase III
genial /// MTCH-24 for oral MTCH-24 - preclinical
12/31/2005:
Cannot proceed with
http://sec.thomsonfn.com/sec/ research until secure funding
SecProd?pid=MzgwYlhOdVA
kWQEQUALSTOEQUALSTO
&transform=result&type=resul
ts&doc_type=10Q&doc_dcn=06567591&cont_
format=HTML&cont_qualifier=
C&doc_product=E&viewer=N
4/2003: licensed to BioVail for
Genvir (acyclovir promanufacturing and marketing in US drug) controlled release
and Canada // 3/5/2005: relation
acyclovir
with Biovail terminated for lack of
progress on Biovail's part // Flamel
is seeking new partner // 6/2005
(company website) In discussions
with potential corporate partners
Rx of acute ghsv
Phase III completed in
Europe with results that
Genvir is as safe and
effective as Valtrex// Phase
III in US to anticipated to
begin end of 2004
6/15/2005:
Pricing to be below that of
http://ir.10kwizard.com/filing.p other prodrugs
hp?repo=tenk&ipage=352594
4&doc=1&num=21&total=105
&source=331&fg=24
Valtrex XR
(Rx) GHSV
Phase I
10/3/2004 - company website
Tolan compounds
(Rx)
Preclinical
ME-609 - Lipsovir (topical
acyclovir)
prevents/supresses cold
sores
Phase III - July 2006 in
South Carolina
7/30/2005: Page 8 on
http://www.techtrans.kent.edu
/AvailableTechnologiesBook.p
df
8/10/2006: posted by
Launch to market may be
possible late 2008
summergirl on HHP:
http://www.clinicaltrials.gov/ct
/show/NCT00361881?order=
11
(Rx) reduces pain of
shingles
preparing for Phase III
12/2005:
potential GHSV indication
http://www.medivir.com/v3/en later
/ir_media/reports/pdf/2006/Fi
nState-060216.pdf
NB-001
(Rx) topical for cold sores
Phase II completed 9/2005demonstrated safety and
efficacy - Phase III to begin
2006
available for licensing
NB-004
(Rx) topical for genital hsv2 poised to enter Phase II
Upsher-Smith Laboratories, Inc.
(conducting the research)
PCL-016 (OHSV) &
FSR488 (GHSV)
(Rx) oral & genital HSV;
topical // both target
ZincFinger Proteins
7/21/2005: company press
release //
http://www.nanobio.com/New
s_NB-001_Phase2.html
10/16/2006:
http://www.nanobio.com/licen
se.html
10/16/2006 - company
website
9/2002 - http://www.upshersmith.com/news/newsarticles/
novactyl.html
Vienna, VA
6)
(Rx)
Science behind LEAPS:
www.cel-sci.com/leaps.htm
// gov't funding for CEL1000
technology research
(www.gsk.com)
9)
Kent State University
10)
Medivir
Docherty, Tsai
Sweden
(www.medivir.se)
11)
This license has come back to
MIV-606 (aka RP606 aka
Medivir from Reliant. Reliant did
Valomaciclovir)
conducts lots of useful research on
theis product in the interim which
will allow Medivir to move forward.
Medivir
Sweden
(www.medivir.se)
12)
NanoBio Corporation
(www.nanobio.com)
13)
NanoBio Corporation
(www.nanobio.com)
14)
Novactyl
Louis, MO
St.
Phase II (PCL-016)
Findings: A significant
proportion of subjects on the
highest dose of NB-001 had
healing two or more days
earlier than the control
group.
15)
Quigley Pharma
(www.quigleyco.com)
uses naturally derived compounds QR-444 & QR-446
(Rx) ocular & genital
Pre-clinical
(Rx) and (P)
preclinical - anticipates
clinical trials ???
Pennsylvania and botanicals // University of
Pittsburg
16)
Resveratol
Royalmount Pharmaceuticals
Canada
17)
Transport Pharmaceuticals
18)
Vironova
Nexus Therapeutics
acyclovir (40 times stronger (Rx) cold sore using device Phase III initiated (5/2005)
than usual)
VN-H110
(T) for Herpes 1-8
Preclinical
DES10
prevention
preclinical
2/2006 5/22/2006: pursuing
http://www.quigleyco.com/ne research further
ws/nr/021306.php //
5/22/2006:
http://www.quigleypharma.co
m/index.php?mact=News,cntn
t01,detail,0&cntnt01articleid=
5&cntnt01returnid=77
Found by reallyworried
5/31/2005:
http://www.biospace.com/ne
ws_rxtarget.aspx?RxTargetID
=24
(vironova.com)
Microbicides/Prevention
1)
AusAm Biotechnologies
collaborating with NIH
New York
(www.ausambiotech.com)
2)
3)
2/24/2004 - press release on 10/16/2006: can no longer
company website //
locate website
http://www.ausambiotech.co
m/content/news/pr022404a.ht
ml
San Francisco, CA
(www.cellegy.com)
acquired Biosyn 10/8/2004 // Family Savvy (aka C31G)
Health International, US Agency for
International Development,
CONRAD
8/2006:
http://www.cellegy.com/newsr
oom/press/28aug06.html //
10/16/2006: co website:
http://www.cellegy.com/produ
cts/savvy.html
GlaxoSmithKline (GSK)
Corixa
12/10/2003 - Corixa website
Cellegy Pharmaceuticals, Inc.
(www.gsk.com)
prevention & contraceptive Phase III for HIV prevetion:
in Nigeria & Ghana //
8/2006: Nigerian study
stopped - population not
providing statistically
significant data
Phase III for contraception:
began 10/2004 in US - still
ongoing
Herpevac study of Simplirix (P) vaccine for GHSV in
Phase III (4 year trial
women w/o HSV1 or HSV2 started abt 1/2003)
primary indication is for HIV
but anticipates HSV and
HPV indication // 12/2004:
http://www.cellegy.com/prod
ucts/savvy.html…studies to
be completed by 2nd half of
2006 with NDA filing
anticipated early 2007 //
at least the 2nd Phase III
trial // 12,000 volunteers in
trials thus far
Pre clinical
4/30/2005 11/2005
http://news.bbc.co.uk/2/hi/hea http://www.news.harvard.ed
lth/4483155.stm
u/gazette/2005/12.15/09herpes.html 12/2005:
http://focus.hms.harvard.edu
/2005/Dec16_2005/therapeu
tics.shtml
Phase III begins 10/2005 in 10/25/2005: company website 2/24/2005: demonstrating
Africa. Expected to last 3-4 press release
effectiveness against
years
herpes!!!
http://www.betterhumans.co
m/News/news.aspx?articleI
D=2005-02-24-3
4)
Harvard Medical School
Judy Lieberman/Dr. Knipe
long lasting gel using
small interfering RNAs
5)
Indevus Pharmaceuticals
licensed from Procept, Inc.
PRO2000 using 2prevention
naphthalene sulfonic acid
formaldehyde condensate,
sodium salt - fractionated //
female controlled // possibly
contraceptive
Rush-Presbyterian-St.Luke's
Medical Center
Amphora (aka Acidform)
prevention and contraceptive Phase II clinical trial for
8/1/2006:
targetting 2010 market date
prevention of HIV/HSV later http://biz.yahoo.com/bw/0608
in 2006 01/20060801005194.html?.v=
1
CONRAD, TOPCAD, CICCR
Ushercell (aka Cellulose
sulfate)
prevention and contraceptive Phase III trial for HIV and
other STD prevention (incl
hsv1 & hsv2) in Africa
(began January 2004)//
Phase II for BV (Jan 2006)
will last 6 months // Phase II
for contraception completed
(Jan 2006)
1/23/2006:
http://www.polydex.com/v2/ne
ws/06-01-23.html
1/26/2006http://www.polydex.
com/v2/news/06-01-26.html
1/2007:http://www.polydex.co
m/v2/news/07-01-31.html
9/2007:
http://www.polydex.com/v2/ne
ws/09-17-07.html
prevention *kills virus
Phase III March 2004 for 3
without killing sperm so user years in Africa // 6/2006:
can become pregnant"
enrollment completed //
Data collection to continue
until March 2007. Data
analysis by end of 2007
10/16/2006: co website
(www.interneuron.com)
6)
Global Microbicide Project(Virginia)
(www.gmp.org)
Instead Sciences
www.amphoragel.com
7)
Polydex Pharmaceuticals Toronto,
Canada
(www.polydex.com)
Univ of Cape Town, Medical Univ of Carraguard (aka PC-515)
Southern Africa, Medical Research
New York
(www.popcouncil.org/biomed/candidate.ht Council
ml)
8)
Population Council
9)
ReProtect, Inc
Maryland
(www.reprotect.com)
NIH , NIAID, FHI
BufferGel
extended prevention
prevention, contraceptive
Trial for HPTN-035 (for
10/14/2004 HIV, HSV, BV & other stds) http://www.hptn.org/research
_studies/HPTN035.asp //
Phase II/IIb starting
November 2004, anticipated 10/16/2006:
30 month duration in Africa // http://www.reprotect.com/pro
ducts.shtml
data expected in 2006
Trial CCN-003 (for
contraception and bv) Phase
III ending mid 2004
11/15/2004: email from
Gary Usher to goodgirl…the
strategy is to get the
product to market ASAP
possible via a Bactrial
Vaginosis indication
1/23/2006: results from BV
study expected by end of
2006 1/2007: study
stopped b/c was increasing
risk of HIV transmission
9/2007: study found
Ushercell to be safe but
ineffective in treatment of
BV
primary indication is for HIV
but kills HSV and HPV in lab
tests in vivo and in vitro
primary indication is for HIV
but kills HSV and HPV in lab
tests in vivo and in vitro //
being tested with PRO2000
// 12/11/2004:
http://www.wsvn.com/featur
es/articles/medicalreports/D
BM852/…"could be on the
market in a year or two"
10)
Starpharma
NIH funding (10/2005)
Melbourne, Australia
(www.starpharma.com)
11)
University of Texas - Dr Simmons
1)
AlphaVax
VivaGel (aka SPL7013)
prevention and in 7/2006
topical micobicide (vaginal found to possibly be
contraceptive
gel) for women to protect
themselves against HIV and
other STDs including HSV
(P) prevention G HSV1 &
possibly HSV2
Phase I human safety study
succesfully completed
8/24/2006: Phase I begins
for safety in 36 men in
Australia
1/9/2006:
http://www.natap.org/2006/HI
V/011206_01.htm // receives
fast track status from FDA
6/26/2006:
http://www.pipelinereview.co
m/joomla/content/view/4742/1
06/ 9/2006: Annual Report
2006
Preclinical
http://research.utmb.edu/web
_brochures/TherapeuticsBiotechnology/Topical%20Mic
robicide%20for%20Prevention
%20of%20Herpes%20Infectio
ns.pdf
Phase I began in 2003
7/20/2005: Vaccine Weekly
article
target market date mid2007
// 4/2006: secures funding
from NiAID for ghsv
indication// 6/2006: filed for
IND for herpes prevention //
7/2006 IND for ghsv trial
granted - trials to be held in
Kenya & San Francisco
Adjuvants
Research Triangle Park, NC
(www.alphavax.com)
2)
Avantogen (used to be Australian
Wyeth-Lederle Vaccine &
Pediatrics division in 1998
ArV (AlphaVax Replicon
(P) and (T) vaccines
Vector) Vaccine Packaging
System //adjuvant to
improve preventative and
therapeutic vaccines
University of Alabama
GPI - 0100
GSK, BioSante, Fred Hutchinson;
Uwashington // see GSK above)
MPL adjuvant used in GSK MPL in combo with GSK
vaccine increases immune
Simplirix
response to antigens in
vaccine
Cancer Technology)
Australia
(www.avantogen.com)
3)
Corixa Corp.
(www.corixa.com)
(T) adjuvant originally used PreClinical
in HSV vaccine by Galenica
Pre-Clinical research on
BioSantes' BioVant
6/15/2005:
http://www.rednova.com/new
s/display/?id=156218&source
=r_health
7/20/2005: "The
company is working with
a number of other
academic and industry
partners on vaccines for
diseases like herpes"
11/6/2004 - company website
Failed Trials
gD2 gB2 vaccine // MFS9
Chiron
Eli Lilly
3M
Resiquimod: immune
modulator to facilitate
endogenous vaccination
increasing cell mediated
immunity to endogenous
HSV2 antigens
vaccine
failed Phase III presumably
because of adjuvant
(Rx) topical gel to decrease failed Phase III - ineffective, 2/24/2003 frequency of OBs for
did not see significant
www.healthscout.com/static/n
GHSV2
results (2/24/2003)
ews/1500928.html
Emmelle Gel
ML Laboratories
ML Labs stopped all activity 9/9/2004 - press release
when it was determined that (company website)
Emmelle is not as effective
as PRO2000.
UK
(www.mllabs.co.uk)
Xenova
failed Phase II
Chiron is now affiliated with
Powdermed
Collaboration with 3M
terminated
primary indication is for HIV
but anticipates HSV and
HPV indication
GSK
TA-HSV
vaccine
10/21/2001 http://www.xenova.co.uk/pdf
s/XenovaPrelim02.pdf#searc
h='TA%20HSV'
Army, navy, NIH, CDC, Corixa,
DynPort
BioVant CAP adjuvant
delivery system using
calcium phosphate
BioVant combined w/HSV2 Pre-clinical
antigens to increase immune
response to antigen
4/29/2004 current research focussing
www.homelanddefensestocks on ricin, anthrax, malaria
.com // company website
press releases
ISS stimulates innate
immune system for use in
(p) and (t) vaccines
adjuvant?
Preclinical
company webiste
Stressgen
R1461 (CoVal Fusion
Protein)
adjuvant for vaccine
Pre-Clinical for HSV
application
technology may transfer to
HSV but they are focusing
research on HPV currently
See Acambis
dI5-29
(P) and (T) vaccine for
HSV2
Preclinical results indicate 10/27/2005: email response
they are ready to proceed to from AVANT to HHP member
human trials
Samson: AVANT returned
patent to Harvard several
years ago
2000 AVANT press release:
they have exclusive
worldwide rights to Harvard
patent //
Keep an eye on…
BioSante Pharmaceutical
(www.biosantepharma.com)
Dynavax
(www.dynavax.com)
5)
Roche
Nutley, NJ
current research focusing on
small pox and anthrax
MISC Companies
Apollon (see Wyeth-Lederle)
AVANT Immunotherapeutics
Massachusetts
(www.avantimmune.com)
Aviron (see MedImmune Vaccine, Inc.)
RAV9395
Australian Cancer Technology
5/31/2005 named changed to
Avantogen
Bayer
2006: created spin-off company
AiCuris to develop anti-infectives
BAY 57-1293
www.bioinfo.com (Antiviral
Agents Bulletin database)
2/2002:acquired by
MedImmune Vaccine, Inc.
Biosyn (see Cellergy)
BioVail
failed partnership with Flamel
Technologies // 3/5/2005: Flamel
terminated agreement for lack of
progress on Biovail's part
Genvir (acyclovir prodrug)
9/2005: Celtic Pharma acquired
Xenova
DISC-Pro
Cantab (see Xenova)
Celtic Pharma
(www.celticpharma.com)
Bermuda/New York/London
Chiron (see PowderMed)
Galenica Pharmaceuticals (see
Australian Cancer Technology)
Harvard University
Immunenetwork
5/20/2003: acquired PowderJect
5/17/2004: created PowderMed
6/23/2004 Australian Cancer
Technology acquired Galenica
Pharmaceuticals
Harvard Medical School (Dr Knipe) dI5-29
, NIH (Dr. Strauss) // 2/26/2008:
dl5-29 being further researched by
Acambis
(P) vaccine
ViraPlex; MTCH-24 aka
Zorex
Oxford, England
(www.powdermed.com)
8/15/2005 acquired by East West
Distributors, Inc
Chiron // PowderJect
10/9/2006 PowderMed is acquired
by Pfizer
ViraPlex; MTCH-24 aka
Zorex
PMED (aka DNA on gold;
(P) and (T) vaccines for
originally PowderJect) DNA HSV2
mediated epidermal delivery
induces both humoral and
cellular immunity
VRI, Inc. (see Avant
Immunotherapeutics)
5/1998 VRI, Inc. became Avant
Immunotherapeutics
Xenova (see Celtic Pharmaceuticals)
8/2005: Acquired by Celtic
Pharmaceuticals
PowderMed
2/20/2006 - company website DISC-Pro is still included in
old Xenova Licensing
Opportunity list 2/2008:
DISC-Pro no longer included
in product line-up
(P) and (T) live virus vaccine Preclinical results indicate 10/27/2005: Dr Strauss email
for HSV2
they are ready to proceed to in response to HHP member
human trials
Samson: still performing
preclinical trials as a lot of
data is required before trials
can begin - Dr Knipe is
discussing clinical trials wth a
biotech
5/31/2001: Acquired by MediTech
Pharmaceuticals
Instead Inc
MediTech Phatrmaceuticals
poised for Phase III
Phase I: clinical trial
completed 8/2004 - data
analysis being performed //
3/31/2006: preparing for
Phase I study in Kansas of
Immunostimulator
12/24/2004 http://www.eurekalert.org/pu
b_releases/2004-12/hmssoe121404.php //
1/9/2005: Dr Knipe awarded
5 year NIH grant
3/31/2006:
Trial began 12/2004 and ran
www.clinicaltrials.gov // Study for 8 months 2/2008: Pfizer
information:
website mentions
http://www.clinicaltrials.gov/ct acquisition of Powdermed
/show/NCT00310271?order= and tecbnology but no
1 10/9/2006:
mention of herpes vaccine
http://mediaroom.pfizer.com/i in current product pipeline
ndex.php?s=press_releases&i
tem=108